{"organizations": [], "uuid": "96a180092a4a1e497bb8600143047f43b88ebe3b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180410.html", "section_title": "Archive News &amp; Video for Tuesday, 10 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-loxo-oncology-and-illumina-to-part/brief-loxo-oncology-and-illumina-to-partner-on-developing-pan-cancer-companion-diagnostics-idUSFWN1RN07L", "country": "US", "domain_rank": 408, "title": "BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.454, "site_type": "news", "published": "2018-04-10T19:27:00.000+03:00", "replies_count": 0, "uuid": "96a180092a4a1e497bb8600143047f43b88ebe3b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-loxo-oncology-and-illumina-to-part/brief-loxo-oncology-and-illumina-to-partner-on-developing-pan-cancer-companion-diagnostics-idUSFWN1RN07L", "ord_in_thread": 0, "title": "BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics", "locations": [], "entities": {"persons": [], "locations": [{"name": "larotrectinib", "sentiment": "none"}], "organizations": [{"name": "illumina", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10 (Reuters) - Loxo Oncology:\n* LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS\n* LOXO ONCOLOGY-PARTNERSHIP TO SEEK APPROVAL FOR VERSION OF ILLUMINA TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS\n* LOXO ONCOLOGY - COMPANIES ALSO PLANNING TO BROADEN CLINICAL UTILITY OF FULL PANEL BY OBTAINING REGULATORY APPROVAL FOR OTHER ASSAY CONTENT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-10T19:27:00.000+03:00", "crawled": "2018-04-11T18:14:44.018+03:00", "highlightTitle": ""}